Search
Food allergy affects up to 10% of Australian infants. It was hypothesized that if parents follow the Australasian Society of Clinical Immunology and Allergy guidelines, Australian food allergy rates may stabilize or decline.
Clinical studies supported by immunological data indicate early life intervention strategies to be promising in reducing the growing global burden of food allergies. The events that predispose to food allergy, including the induction of allergen-specific immune responses, appear to be initiated early in development.
The immunological changes underpinning acquisition of remission (also called sustained unresponsiveness) following food immunotherapy remain poorly defined. Limited access to effective therapies and biosamples from treatment responders has prevented progress. Probiotic peanut oral immunotherapy is highly effective at inducing remission, providing an opportunity to investigate immune changes.
To assess the efficacy and adverse events of epicutaneous immunotherapy with a peanut patch among peanut-allergic children
There was a significant improvement in the management of anaphylaxis after the introduction of intensified physician training programs
Early life innate immune dysfunction may represent a key immunological driver and predictor of persistent food allergy in childhood
Our data indicate epigenetic dysregulation in the early stages of signal transduction through the T cell receptor complex, and likely reflects pathways modified by gene-environment interactions in food allergy
Epidemiological evidence from the past decade suggests a role of vitamin D in food allergy pathogenesis
Maternal supplementation with 900 mg of ω-3 LCPUFA did not change the progression of IgE-mediated allergic disease symptoms or sensitization
Infant feeding in the first postnatal year of life has an important role in an infant's risk of developing food allergy